Bruker (NASDAQ:BRKR) Releases FY 2024 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.360-2.410 for the period, compared to the consensus estimate of 3.590. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.4 billion. Bruker also updated its FY24 guidance to $2.36-2.41 EPS.

Analyst Upgrades and Downgrades

BRKR has been the topic of a number of recent research reports. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. TD Cowen lowered their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday. Citigroup reduced their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday. Barclays decreased their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company dropped their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Performance

Shares of NASDAQ:BRKR traded up $1.51 during midday trading on Thursday, reaching $60.49. The company’s stock had a trading volume of 1,346,609 shares, compared to its average volume of 1,264,657. The firm has a market capitalization of $9.16 billion, a PE ratio of 25.10, a P/E/G ratio of 2.32 and a beta of 1.20. The stock has a fifty day moving average of $63.97 and a 200 day moving average of $66.51. Bruker has a twelve month low of $54.55 and a twelve month high of $94.86. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 24.92% and a net margin of 11.29%. The company had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter in the previous year, the business posted $0.74 EPS. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. On average, equities analysts expect that Bruker will post 2.61 EPS for the current fiscal year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.